17 studies found for:    Pharmacyclics | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Conditions: Follicular Lymphoma;   B-cell Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Ibrutinib;   Drug: rituximab
2 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Ibrutinib
3 Recruiting Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
4 Recruiting Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma Relapsed;   Diffuse Large B Cell Lymphoma Refractory
Interventions: Drug: Ibrutinib, DA-EPOCH-R;   Drug: Ibrutinib, Lenalidomide, DA-EPOCH-R
5 Recruiting Ibrutinib in Combination With Lenalidomide, With and Without Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
6 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Conditions: Marginal Zone Lymphoma;   B-cell Lymphoma
Intervention: Drug: ibrutinib
7 Recruiting A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL
Conditions: Chronic Lymphocytic Leukemia;   Small-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Obinutuzumab;   Drug: Chlorambucil
8 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
9 Not yet recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
10 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
11 Recruiting Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Condition: Metastatic Solid Tumors
Intervention: Drug: PZP115891, PCI-24781
12 Recruiting A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Treated Indolent Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PCI-32765 (Ibrutinib);   Drug: Placebo
13 Recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Placebo
14 Recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
15 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
16 Recruiting A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib
17 Not yet recruiting A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls

Indicates status has not been verified in more than two years